Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tranexamic acid
Drug ID BADD_D02261
Description Tranexamic acid is a synthetic derivative of [lysine] used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent.[L31883] It was first patented in 1957[A230108] and received its initial US approval in 1986.[L31858]
Indications and Usage Dunn CJ, Goa KL: Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999 Jun;57(6):1005-32.
Marketing Status Prescription; Discontinued
ATC Code B02AA02
DrugBank ID DB00302
KEGG ID D01136
MeSH ID D014148
PubChem ID 5526
TTD Drug ID D05HXX
NDC Product Code 12079-2001; 71052-166; 42571-314; 51754-0108; 67457-197; 71335-1957; 69918-301; 60505-6169; 70860-400; 0591-3720; 63629-8838; 67850-041; 50090-5072; 0013-1114; 51552-0513; 38779-3211; 42571-189; 49452-7877; 67850-042; 81999-0001; 43066-008; 72485-107; 68382-891; 39822-1000; 55150-188; 72611-760; 50090-4530; 49452-7876; 12848-1004; 71335-1981; 70121-1398; 51662-1532; 65388-0156; 61990-0611; 63323-563; 65145-106; 23155-166; 38779-2794; 81284-611; 70771-1085; 73309-178; 57218-951; 63629-8599; 51927-0022; 63759-0038; 62991-3131; 69918-300; 17478-017; 0517-0960; 81284-612; 17478-018; 62559-265; 68083-160; 55566-2110; 23155-524
Synonyms Tranexamic Acid | AMCHA | trans-4-(Aminomethyl)cyclohexanecarboxylic Acid | t-AMCHA | AMCA | Anvitoff | Cyklokapron | Ugurol | KABI 2161 | Spotof | Transamin | Amchafibrin | Exacyl
Chemical Information
Molecular Formula C8H15NO2
CAS Registry Number 701-54-2
SMILES C1CC(CCC1CN)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypovolaemic shock24.06.02.0170.014288%Not Available
Hypoxia22.02.02.0030.050010%
Immune system disorder10.02.01.001--Not Available
Intestinal infarction24.04.08.008; 07.15.02.006--Not Available
Joint stiffness15.01.02.003--Not Available
Joint swelling15.01.02.0040.035721%Not Available
Loss of consciousness17.02.04.0040.042865%Not Available
Malaise08.01.01.003--
Menorrhagia21.01.03.0020.021433%
Migraine24.03.05.003; 17.14.02.0010.014288%Not Available
Multiple allergies10.01.03.030--Not Available
Muscle haemorrhage24.07.01.037; 15.05.03.0170.021433%Not Available
Muscle spasms15.05.03.004--
Muscle twitching15.05.03.0050.014288%Not Available
Muscular weakness17.05.03.005; 15.05.06.0010.021433%
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.0070.018637%
Myocardial ischaemia24.04.04.010; 02.02.02.008--Not Available
Myoclonus17.02.05.0080.142885%Not Available
Nasopharyngitis22.07.03.002; 11.01.13.0020.014288%Not Available
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Neurotoxicity17.02.10.002; 12.03.01.0110.042865%Not Available
Night blindness14.12.03.001; 06.02.02.0030.014288%
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Oxygen saturation decreased13.02.01.0040.014288%Not Available
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Pallor24.03.04.001; 08.01.03.032; 23.03.03.0310.014288%Not Available
The 4th Page    First    Pre   4 5 6 7    Next   Last    Total 7 Pages